Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
Abroad (travel likely)RecruitingPHASE2
Conditions
Malignant Solid Tumors
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Ghayas Issa, MD)
Study leads
Ghayas Issa, MD
Principal Investigator
M.D. Anderson Cancer Center